On July 17, 2026 Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology platform, reported it will present three-year clinical efficacy data from its phase 2 trial with personalized cancer vaccine candidate EVX-01 at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026 to be held in Madrid, Spain, from October 23-27, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The data stems from a one-year extension of the phase 2 trial evaluating EVX-01 in patients with advanced melanoma (skin cancer). In the third year, patients received EVX-01 as stand-alone therapy, meaning the data will offer insight into the vaccine’s effect also when not administered in combination with anti-PD-1 therapy. Further, the data may also provide additional insights into potentially enhanced treatment effects and durability of the EVX-01-induced immune response.

"We are looking forward to presenting the data on EVX-01 at the important ESMO (Free ESMO Whitepaper) Congress. This will be an excellent opportunity for us to also discuss the data with stakeholders and potential business partners at a time when pivotal late-stage clinical data are continuing to emerge across the personalized cancer vaccine field," says Birgitte Rønø, CSO & COO of Evaxion.

Convincing results
The three-year data will add to already convincing results from the phase 2 trial. The two-year data demonstrated an Objective Response Rate (ORR) of 75% as 12 out of 16 patients had objective clinical responses, with four patients obtaining a complete response. Additionally, a durable clinical benefit was observed as 92% of patients were still responding at two years follow-up and no relapses were observed.

54% of patients had a deepened response during treatment, improving from stable disease or partial response to partial or complete response. Tumor reduction (target lesions) was observed in 15 out of the 16 patients enrolled in the trial.

In the trial, EVX-01 induced an immune response in all patients, with 86% of the targeted neoantigens generating potent specific T-cell responses.

The phase 2 trial investigated EVX-01 in patients with advanced melanoma. Each patient enrolled in the trial received a unique vaccine designed and manufactured based on their individual biology. In the first two-years, patients received EVX-01 in combination with MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy, KEYTRUDA (pembrolizumab). In the third year, a subset of patients received EVX-01 as stand-alone therapy. KEYTRUDA is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Presentation details
Abstract title: EVX-01, a personalized cancer vaccine, induces sustained T-cell responses and durable disease control in advanced melanoma after three-year of follow-up
Presentation#: 2006P
Location: Poster Area – Hall 5
Topic: Investigational immunotherapy
Date/Time: October 24, 2026, at 12:00 – 12:45 CET
Presenter: Dr. Muhammad Adnan Khattak, Director, Oncology, One Clinical Research, Hollywood Private Hospital & Edith Cowan University, Perth, WA, Australia

About EVX-01
EVX-01 is a personalized peptide-based cancer vaccine intended for first-line treatment of multiple advanced solid cancers. It is Evaxion’s lead clinical asset.

Designed with our AI-Immunology platform, EVX-01 and is tailored to target the unique tumor profile and immune characteristics of each patient. It engages the patient’s immune system to fight off cancer by mounting a targeted response against tumors.

About melanoma
Melanoma accounted for approximately 1 in 5 of the 1.5 million new skin cancer cases estimated globally in 2020 with approximately 325,000 cases and 57,000 deaths. The global burden from melanoma is estimated to increase to 510,000 new cases and 96,000 deaths by 2040 (Arnold et al., JAMA Dermatology 2022). The global market for melanoma treatments is estimated to grow to $7.4 billion by 2029 (GlobalData).

(Press release, Evaxion, JUL 17, 2026, View Source [SID1234669287])

On July 16, 2026 Trethera Corporation ("Trethera"), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, reported a comprehensive peer-reviewed manuscript describing deoxycytidine kinase (dCK) as a promising novel metabolic target that may enable a new class of precision cancer therapies. The article, published in Nucleosides, Nucleotides & Nucleic Acids, reviews decades of scientific study of the deoxyribonucleoside salvage pathway and highlights TRE-515 as the first dCK inhibitor to advance into human clinical testing.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The review describes how many tumors become increasingly dependent on the salvage pathway to maintain DNA precursor pools during rapid proliferation, DNA damage, and therapeutic stress. By selectively inhibiting the salvage pathway’s rate-limiting enzyme dCK, TRE-515 is designed to exploit a metabolic vulnerability that may exist across multiple tumor types while sparing normal tissues that primarily rely on de novo nucleotide synthesis.

The publication summarizes evidence demonstrating that specific genetic alterations—including BRCA2 deficiency and mutant p53—increase tumor reliance on dCK-mediated deoxyribonucleoside salvage. The authors further review emerging preclinical data supporting dCK inhibition in combination with DNA-damaging agents and radiation therapy that cause replication stress, suggesting that nucleotide salvage inhibition may enhance the activity of standard-of-care therapies across multiple tumor types.

"The data linking deoxyribonucleoside salvage to tumor growth and survival are very compelling but underappreciated relative to the historical focus on the de novo synthesis pathway," said Dr. Peter M. Clark, Professor of Molecular and Medical Pharmacology at the David Geffen School of Medicine at UCLA and publication first author. "This review highlights growing evidence that many tumors also depend on the deoxyribonucleoside salvage pathway under conditions of replication stress and DNA damage."

"True innovation doesn’t come from improving yesterday’s medicines—it comes from opening entirely new biological pathways for therapy," said Dr. Ken Schultz, Trethera Chief Executive Officer and publication co-author. "This publication reinforces the growing recognition that targeting dCK represents a new frontier in precision cancer medicine and positions TRE-515 at the forefront of that opportunity."

The publication also highlights the translational tools supporting TRE-515 development, including pharmacodynamic biomarkers designed to measure dCK activity and pathway inhibition to help guide future clinical studies.

Biochemical pathways for the supply of deoxyribonucleoside triphosphate pools. TRE-515 blocks the salvage pathway, which becomes upregulated during cancer growth and autoimmune disease.

(Press release, Trethera, JUL 16, 2026, View Source [SID1234669280])

On July 16, 2026 Adlai Nortye Ltd. (NASDAQ: ANL) ("Adlai Nortye" or the "Company"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, reported that the first patient has been dosed in the United States in the intermittent weekly dosing (QW) arm of the ongoing Phase 1 clinical trial of AN9025, a pan-RAS(ON) inhibitor.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Dosing the first U.S. patient with AN9025 on an intermittent weekly schedule is a significant milestone and advances our clinical strategy to evaluate AN9025 with a differentiated approach. We believe based on our preclinical data that weekly dosing could widen the therapeutic window, enabling higher dosing and/or improving tolerability and combinability by giving normal tissue a break while maintaining tumor RAS-signaling inhibition," said Dr. Archie Tse, President, Head of Research and Development at Adlai Nortye. "We look forward to efficiently progressing the global clinical development of AN9025 and generating meaningful data to support its future advancement. We continue to plan to share initial Phase 1 dose escalation data in 1H27 from the QD arm, with a potential early look at the QW arm."

The Phase 1 study is a first-in-human, multicenter, open-label trial designed to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of AN9025 in patients with advanced or metastatic solid tumors harboring RAS mutations. This trial is being conducted by Adlai Nortye in collaboration with Jiangsu Aosaikang Pharmaceutical Co. Ltd. ("ASK Pharm") as a multi-regional clinical trial ("MRCT") pursuant to a license agreement, under which Adlai Nortye retains ex-China rights to AN9025, while ASK Pharm holds rights in mainland China, Hong Kong and Macao. With this announcement, both the QD and QW dose escalation arms are currently enrolling.

About AN9025

AN9025 is an oral small molecule pan-RAS(ON) inhibitor with best-in-class potential, designed to target a broad spectrum of RAS mutations across various tumor types. Preclinical studies have demonstrated that AN9025 effectively inhibits RAS-mutant cancers with potent and durable efficacy, including pancreatic, lung, and colorectal adenocarcinomas, and shows comparable or superior results relative to a benchmark agent of the same class.

(Press release, Adlai Nortye Biopharma, JUL 16, 2026, View Source [SID1234669279])

On July 16, 2026 Remix Therapeutics (Remix), Inc., a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, reported Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix will present at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Drug Discovery and Development Conference taking place July 21-24, 2026 in Boston.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The AACR (Free AACR Whitepaper) Drug Discovery and Development Conference brings together leaders across oncology research and drug development, making it an ideal venue to provide a corporate update and showcase our progress with the ongoing Phase 1/2 ARIA study of REM-422," said Dr. Smith. "The clinical activity, durability of response and favorable safety results observed to date reinforce the potential of our RNA processing approach, and we look forward to discussing how this modality may offer a new therapeutic option for patients with MYB-driven cancers, including adenoid cystic carcinoma."

Presentation Details:

Session Title: Biotech Spotlight Session 1: Novel Therapeutics
Date and Time: July 24, 2026 at 2:50 PM ET
Location: Sheraton Boston Hotel

About REM-422
REM-422 is a potent, selective, and oral small molecule mRNA degrader that induces the reduction of MYB mRNA and subsequent protein expression. REM-422 functions by facilitating the incorporation of a poison exon in the MYB mRNA transcript, leading to nonsense-mediated decay of the transcript. REM-422 is currently in a Phase 1/2 clinical study in Adenoid Cystic Carcinoma (ACC) and a Phase 1 clinical study in Acute Myeloid Leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS). The U.S. Food and Drug Administration granted REM-422 Orphan Drug Designation for ACC and AML and Fast Track designation for ACC.

About the ARIA (A study of REM-422 In Adenoid cystic carcinoma) Clinical Trial
This Phase 1/2, open-label, non-randomized, multicenter study (NCT06118086) is investigating REM-422 in patients with recurrent, metastatic or unresectable Adenoid Cystic Carcinoma (ACC). The study includes a Dose Escalation Phase and a Dose Expansion Phase. The purpose of the Dose Escalation Phase is to determine the maximum tolerated dose and/or recommended Phase 2 dose (RP2D) of REM-422 in patients with recurrent, metastatic, or unresectable ACC. The purpose of Dose Expansion is to further evaluate the safety and anti-tumor activity of the REM-422 RP2D in biomarker positive patients.

About Adenoid Cystic Carcinoma
Adenoid cystic carcinoma (ACC) is a solid tumor that most commonly arises in the salivary glands characterized by frequent recurrent, perineural invasion and dysregulation of the MYB oncogene. Depending on the location of the tumor, symptoms may include numbness of the face, difficulties swallowing, changes in vision, or difficulty breathing, among others. Many therapeutic approaches, such as chemotherapy, kinase inhibitors, and immunotherapy have been studied in ACC with modest or disappointing results, and there remain no approved treatment options.

(Press release, Remix Therapeutics, JUL 16, 2026, https://www.globenewswire.com/news-release/2026/07/16/3328319/0/en/remix-therapeutics-to-present-at-aacr-drug-discovery-and-development-conference.html [SID1234669278])

On July 16, 2026 Umoja Biopharma, Inc., a clinical-stage biotechnology company committed to delivering innovative and potentially curative immunotherapies for patients with cancer and autoimmune diseases, reported that the U.S. Food and Drug Administration (FDA) recently cleared its Investigational New Drug (IND) application for UB-VV400, a CD22-directed in vivo CAR T cell therapy candidate for adults with relapsed/refractory B cell malignancies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"UB-VV400 is our second VivoVec based in vivo CAR T cell program to advance to U.S. clinical trials," said Luke Walker, M.D., Chief Medical Officer of Umoja Biopharma. "Generating CAR T cells within a patient’s body would have the potential to transform clinical practice. We designed this Phase 1/2 trial to address a critical, real-world unmet need for patients, including those who have progressed after prior CAR T cell treatment. We remain highly encouraged by the early clinical activity and safety profile seen in the patients treated in our investigator-initiated trial of UB-VV400, and we look forward to sharing initial clinical data."

The Phase 1/2 VIBRANT-1 study of UB-VV400 will open soon at U.S. clinical sites, with the first patient anticipated to be dosed in Q3 this year. The open-label, dose escalation and expansion trial is designed to evaluate safety and tolerability, pharmacokinetics and pharmacodynamics, and preliminary antitumor activity of UB-VV400 in combination with rapamycin in patients with relapsed/refractory B cell malignancies.

Initial clinical data from the investigator-initiated trial of UB-VV400 in China is expected to be shared at a major medical meeting in the second half of 2026.

(Press release, Umoja Biopharma, JUL 16, 2026, View Source [SID1234669277])